What is Immunetics?
Immunetics operates at the intersection of immunology, molecular biology, and veterinary diagnostics, providing a comprehensive suite of biomedical products. Its core offerings include advanced antibodies, diagnostic test kits, and proprietary assay technologies designed to facilitate both foundational research and clinical applications. By maintaining a robust global supply chain, the company serves as a critical partner for laboratories seeking reliable, high-performance reagents. Its market position is defined by a commitment to scientific rigor and the commercialization of essential tools that drive progress in life sciences.
How much funding has Immunetics raised?
Immunetics has raised a total of $8.1M across 5 funding rounds:
Grant
$2.4M
Grant
$500K
Unspecified
$629K
Grant
$3.7M
Debt
$835K
Grant (2011): $2.4M with participation from National Institutes of Health
Grant (2011): $500K led by The Massachusetts Life Sciences Center
Unspecified (2012): $629K, investors not publicly disclosed
Grant (2012): $3.7M featuring National Institutes of Health
Debt (2014): $835K, investors not publicly disclosed
Key Investors in Immunetics
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical grant support for scientific advancement.
The Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center is an investment agency that fosters innovation by supporting workforce development and the commercialization of life sciences technologies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Immunetics?
With the recent influx of $835K, Immunetics is well-positioned to accelerate its R&D initiatives and expand its footprint in the molecular diagnostics market. The strategic focus will likely shift toward enhancing its gene editing capabilities and scaling production to meet the rising demand for specialized immunological assays. As the company transitions into this next phase of maturity, the emphasis will remain on maintaining its reputation for quality while exploring new avenues for commercial growth and collaborative research partnerships. The firm's ability to secure diverse funding sources, ranging from government grants to debt financing, provides a stable foundation for long-term innovation and market leadership.
See full Immunetics company page
